Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goki Suda

Showing results (81-90 of 148) with videos related to

Pageof 15
Sort By:
Journal of Gastroenterology|March 20, 2017
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapyGoki Suda, Koji Ogawa, Yoshiya Yamamoto, et al.
International Journal of Molecular Sciences|March 11, 2023
Prediction Model with <i>HLA-A*33:03</i> Reveals Number of Days to Develop Liver Cancer from Blood TestNao Nishida, Jun Ohashi, Goki Suda, et al.
Targeted Oncology|September 2, 2024
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab TreatmentTakuya Sho, Goki Suda, Masatsugu Ohara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 21, 2016
Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infectionJun Ito, Goki Suda, Yoshiya Yamamoto, et al.
Carcinogenesis|September 21, 2017
Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinomaOsamu Maehara, Goki Suda, Mitsuteru Natsuizaka, et al.
Journal of Gastroenterology|November 19, 2020
Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infectionKazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, et al.
Carcinogenesis|May 26, 2020
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signalingTaku Shigesawa, Osamu Maehara, Goki Suda, et al.
Journal of Gastroenterology|December 17, 2009
Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cellsYuki Nishimura-Sakurai, Naoya Sakamoto, Kaoru Mogushi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 20, 2017
Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled studyGoki Suda, Jun Ito, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 25, 2024
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective studyZijian Yang, Goki Suda, Takuya Sho, et al.
Pageof 15

Showing results (81-90 of 148) with videos related to

Sort By:
Pageof 15
Journal of Gastroenterology|March 20, 2017
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapyGoki Suda, Koji Ogawa, Yoshiya Yamamoto, et al.
International Journal of Molecular Sciences|March 11, 2023
Prediction Model with <i>HLA-A*33:03</i> Reveals Number of Days to Develop Liver Cancer from Blood TestNao Nishida, Jun Ohashi, Goki Suda, et al.
Targeted Oncology|September 2, 2024
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab TreatmentTakuya Sho, Goki Suda, Masatsugu Ohara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 21, 2016
Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infectionJun Ito, Goki Suda, Yoshiya Yamamoto, et al.
Carcinogenesis|September 21, 2017
Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinomaOsamu Maehara, Goki Suda, Mitsuteru Natsuizaka, et al.
Journal of Gastroenterology|November 19, 2020
Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infectionKazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, et al.
Carcinogenesis|May 26, 2020
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signalingTaku Shigesawa, Osamu Maehara, Goki Suda, et al.
Journal of Gastroenterology|December 17, 2009
Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cellsYuki Nishimura-Sakurai, Naoya Sakamoto, Kaoru Mogushi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 20, 2017
Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled studyGoki Suda, Jun Ito, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 25, 2024
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective studyZijian Yang, Goki Suda, Takuya Sho, et al.
Pageof 15